AIM Immunotech Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AIM Immunotech Inc. on August 5, 2026, covering events as of July 31, 2026. The Company, incorporated in Delaware and trading on NYSE American under the symbol "AIM," reported the termination of a material definitive agreement regarding its equity distribution program.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the terminated equity distribution agreement:
- Shares Sold: 3,200,736 shares of common stock.
- Gross Proceeds: Approximately $2.8 million.
- Period of Sales: April 1, 2025, to July 31, 2026.
- Termination Penalties: None incurred.
Material Changes
The primary material change is the mutual termination of the Equity Distribution Agreement with Maxim Group LLC, originally dated April 1, 2025, and amended on April 10, 2026. The termination is effective August 15, 2026. Consequently, the Company will no longer be able to offer or sell additional shares of common stock under this "at the market" offering structure.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of the equity distribution program. The Company stated it does not intend to issue or sell any additional shares under the agreement prior to its termination. The full text of the Termination Agreement is referenced as an exhibit to be filed in the upcoming Form 10-Q for the period ended June 30, 2026.
Key Facts for Investor Verification
- Verify the effective date of the termination (August 15, 2026) and confirm no further shares can be sold under the Maxim Group agreement.
- Review the upcoming Form 10-Q for the period ended June 30, 2026, to access the full text of the Termination Agreement.
- Confirm the total capital raised ($2.8 million) and share count (3,200,736) from the program to assess dilution impact.
- Check for any new financing plans or alternative capital raising strategies in subsequent filings, as the primary ATM facility is now closed.